Hubert Czerniak - Ratunek dla jelit, czyli maślan sodu! Badania nie pozostawiają żadnych wątpliwości

Czerniak presents this as the simplest functional test for gut barrier integrity. He reasons that the intestinal lining is made of enterocytes held together by tight junction proteins (tancunction). When butyrate or niacin activate the GPR109a receptor on dendritic cells, it strengthens those junctions and promotes mucus (mucin) production. If the junctions are loose, undigested food molecules, bacterial fragments, and pigments like betalain pass into the blood. The beet test gives immediate feedback: no colour means the gut is well sealed; red urine signals a breach. This self‑test avoids expensive lab assays and lets you track whether interventions like butyrate, niacin, or dietary fiber are working to heal the gut. He recommends it alongside the “siara” (colostrum) protocol mentioned in a previous episode for gut repair.

Czerniak differentiates soluble and insoluble fiber. Soluble fiber absorbs water and forms a lubricating gelatinous mass that lets stool slide through the gut without abrasion. Insoluble fiber soaks up water without dissolving, swelling to create a larger, soft faecal mass. Together, they function like a gun‑barrel brush (wycior), scraping the intestinal wall and preventing faecal stones. He contrasts Western diets, which often lead to hard, sticky stools that adhere to the wall and cause local chronic inflammation progressing to cancer over years, with Asian diets rich in fiber and turmeric, where 2‑3 bowel movements a day are common and colon cancer is rare. The fiber also directly feeds bacteria that convert it to butyrate, tying mechanical and microbial benefits together. He recommends both types of fiber at every meal to mimic the protective pattern seen in traditional high‑fiber cultures.

Czerniak notes that while butyrate and niacin are classic agonists of the GPR109a receptor on dendritic cells and macrophages, nature provides other options. Reishi and shiitake mushrooms have compounds that also dock onto this receptor, delivering the same cascade: reduced inflammatory cytokines, promotion of regulatory T‑cells, and improved mucin production. He mentions this in passing but frames it as part of a broader toolkit—grzybki są cool—to seal the gut and cool inflammation. No specific preparation or dosage is given, implying that culinary or supplemental use can be adopted as a supportive measure alongside fiber and butyrate.

Czerniak cites Dr. Xiaoling’s work, noting that the immune‑programming function of gut dendritic cells (CD103⁺) depends on vitamin A. When these cells process antigens in the presence of vitamin A and butyrate, they instruct T‑cells to become regulatory rather than inflammatory. He combines this with the observation that low vitamin D3 is a risk factor for autoimmune disease and likely contributes to the microbiome damage that leads to diabetes. The speaker doesn’t give specific doses but links the global trend of poor‑quality food, low sunlight, and medical interventions that harm the microbiome to a deficiency‑driven breakdown in tolerance. He therefore frames vitamin A and D3 as indispensable co‑factors in the gut‑immune axis.

Czerniak explains that gut bacteria ferment dietary fiber into SCFA. The host’s digestive enzymes cannot break down cellulose and other fibers, so the bacteria do it. However, different bacterial families produce different SCFA profiles. He highlights that bacteria such as Bacteroides and Clostridium tend to produce very short (1‑2 carbon) SCFA that drive inflammation, whereas Firmicutes (including Faecalibacterium and Subdoligranulum) produce butyrate (4 carbons) and longer anti‑inflammatory SCFA. He ties this directly to type 1 diabetes: studies show diabetic children harbor more Bacteroides/Clostridium and fewer butyrate‑producing species, shifting the SCFA balance toward inflammation. This finding suggests that merely increasing total SCFA isn’t enough – you must specifically boost butyrate producers to calm the immune system.

He describes how butyrate (and other long‑chain SCFA) signal through GPR41 and GPR43 receptors on pancreatic beta cells. This increases the production of cathelicidin, a smart antimicrobial peptide, and boosts beta‑cell viability, proliferation, and insulin biosynthesis. Simultaneously, butyrate suppresses glucagon – the hormone that raises blood sugar – and stimulates intestinal L‑cells to release glucagon‑like peptide‑1 (GLP‑1). GLP‑1 slows gastric emptying, curbs hunger, and further enhances insulin secretion while protecting beta cells from apoptosis. This dual action on insulin/glucagon and appetite makes butyrate a potential adjunct for diabetes prevention and management. He contrasts this with the pharmaceutical approach of gliptins, which also raise GLP‑1 but inhibit the DPP‑4 enzyme, causing a cascade of harmful effects (see separate entry).

He explains that children with ASD (autism spectrum disorder) often have a deficiency of the DPP‑4 enzyme in their gut due to a damaged microbiome. Without this enzyme, casein and gluten are not broken down into tiny fragments; instead, opioid‑like peptides such as β‑casomorphin enter the bloodstream. These peptides activate mu‑opioid receptors, effectively “drugging” the child. The speaker warns that gliptins, by pharmacologically inhibiting DPP‑4 to elevate GLP‑1, recreate that very situation in anyone taking them. He further cites research that gliptins worsen allergic reactions and autoimmune inflammatory diseases, making them a dangerous trade‑off. He strongly advises against their use and suggests butyrate as a natural, side‑effect‑free way to boost GLP‑1.

Czerniak reports that Dr. Xiaoling from Utrecht studied how gut microbiota shape the immune system from birth. 2FL, an oligosaccharide in human milk, selectively stimulates Bifidobacterium and Prevotella while inhibiting Helicobacter, Salmonella, and rotavirus. This early microbial seeding determines whether the infant’s dendritic cells will promote regulatory (anti‑inflammatory) or pro‑inflammatory T‑cell pathways. A disruption – via chemical damage (mercury, thimerosal from medical procedures), vitamin D3/A deficiency, or antibiotics – leads to a microbiome that produces too many pro‑inflammatory short‑chain SCFA. This, he says, explains the yearly 1.8% rise in type 1 diabetes incidence, which cannot be accounted for by genetics alone. The protection is lifelong because the immune‑programming window occurs in the first months of life.